<DOC>
	<DOC>NCT01569438</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of a single dose level of AF-219 in female subjects with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.</brief_summary>
	<brief_title>The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome</brief_title>
	<detailed_description>This study is a double-blind, placebo-controlled, randomized trial designed to assess the efficacy and safety of a single dose level of AF-219 in female subjects with moderate to severe IC/BPS. The study will consist of 4 phases: Screening, Baseline, Treatment, and Follow-up.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<criteria>Women Women of child bearing potential must not be pregnant during the study and must use two forms of birth control Clinical evidence of IC/BPS Have provided written informed consent History of diseases that can be confused for IC/BPS Unable to void spontaneously Immunosuppressant, intravesicular, nerve stimulator or opioid treatment during the study and for certain periods prior to start of the study. Changes to doses of ElmironÂ®, antidepressant, alphaadrenergic antagonist, H1 antagonist, or antimuscarinic treatment within a certain period prior to the start of the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>